Immunotherapy
News and reporting on cancer immunotherapy.
UK Consortium Launches With Public-Private Funding to ID Immunotherapy Biomarkers
The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.
Called optiPRM, the approach could help detect cancer neoantigens in patient tumor samples for applications like the development of personalized cancer vaccines.
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
Tumor Gene Expression Signature Linked to Chemotherapy Response in Colon Cancer Cases
Based on hundreds of stage II and III colon cancer samples, researchers uncovered and validated a 10-gene signature linked to adjuvant chemotherapy response.